Laura and Marina presented the complimentary patent law CLE webinar, “Update: Written Description and Enablement Requirements under 35 U.S.C. § 112”, on September 22.

This program provided an update on the written description and enablement requirements under 35 U.S.C. § 112, including:

• Aftermath of Amgen v. Sanofi
• Kite v. Juno – written description applied to CAR T claims
• Types of claims that may satisfy written description requirement
• Functional limitations
• Nalproprion Pharmaceuticals v. Actavis Laboratories —equivalent language
• Software: MCRO v. Bandai Namco Games, and Taylor v. Iancu

PRESENTERS:
Laura Smalley
Partner, Harris Beach Intellectual Property and Business and Commercial Litigation Practice Groups
• Prosecutes patents in the chemical and biotechnology fields and has a technical background in chemistry, including organic and analytical chemistry
• Speaker at AIPLA Annual Meeting 2018: Regulatory and IP Issues for Immunotherapies Including CAR-T and Antibody Technologies
• Named to Super Lawyers (Intellectual Property) and Best Lawyers (Commercial Litigation) lists

Marina Plotkin
Partner, Harris Beach Intellectual Property Practice Group and Medical and Life Sciences Industry Team
• Utilizes the combination of pharmacy and legal credentials to provide strategic insight on complex litigation issues
• Also focuses on defense of product liability litigation involving pharmaceuticals, medical devices, compounded preparations, and biologics
• Speaker at American Society for Pharmacy Law and Pharmacists Society of the State of New York